Serum interleukin-6 levels in uterine malignancies. Preliminary data

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Interleukin-6 (IL-6) is a cytokine with known roles in inflammation and immunity.
• Its potential involvement in cancer progression, particularly uterine malignancies, requires further investigation.

Purpose of the Study:

• To investigate the association between serum Interleukin-6 (IL-6) levels and the presence and stage of cervical and endometrial cancer.
• To compare IL-6 levels in patients with uterine malignancies versus those with benign uterine disease or cervical intraepithelial neoplasia (CIN).

Main Methods:

• Serum samples were collected at diagnosis from patients with endometrial cancer, cervical cancer, CIN, and benign uterine disease.
• Interleukin-6 (IL-6) levels were quantified using an enzyme-immunoassay.
• Statistical analysis was performed to compare IL-6 detection rates across different groups and disease stages.

Main Results:

• Detectable serum IL-6 levels were found in 44% of cervical cancer patients and 11% of endometrial cancer patients.
• Higher IL-6 levels correlated with advanced stages of both cervical (stage IIb-IV) and endometrial cancer (stage III-IV).
• IL-6 was detected less frequently in patients with benign uterine disease (9%) and CIN (11%).

Conclusions:

• Preliminary findings suggest that elevated serum Interleukin-6 (IL-6) may be associated with the progression of cervical and endometrial cancers.
• IL-6 could potentially serve as a biomarker for uterine malignancies, particularly in advanced stages.